N4 Pharma PLC Cash Flow Conversion Efficiency
N4 Pharma PLC cash flow conversion efficiency. Based on the latest financial reports, N4 Pharma PLC (N4P) has a cash flow conversion efficiency ratio of -0.251x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-444.37K ≈ $-54.07 USD) by net assets (GBX1.77 Million ≈ $215.03 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of N4 Pharma PLC (1991–2024)
Cash flow conversion efficiency of N4 Pharma PLC from 1991 to 2024. This chart illustrates how N4 Pharma PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View N4P live share price for real-time trading data and today's change.
N4 Pharma PLC Cash Flow Conversion Ratio Explained
N4 Pharma PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
N4 Pharma PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of N4 Pharma PLC ranked by their cash flow conversion efficiency. Also see N4P market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
URU Metals Ltd
LSE:URU
|
0.356x |
|
G2Power Co. Ltd.
KQ:388050
|
0.059x |
|
Chess Depositary Interests 1:1 Deferred Settlement
AU:AIIDA
|
N/A |
|
Seed Innovations Ltd
LSE:SEED
|
-0.032x |
|
FANDIFI TECHNOLOGY CORP.
F:TQ4
|
N/A |
|
Ahlers AG
F:AAH
|
0.000x |
|
Tertiary Minerals Plc
LSE:TYM
|
-0.361x |
|
Allianz Malaysia Bhd
KLSE:1163PA
|
-0.070x |
Annual Cash Flow Conversion Efficiency for N4 Pharma PLC (1991–2024)
The table below shows the annual cash flow conversion efficiency of N4 Pharma PLC from 1991 to 2024. Review N4 Pharma PLC free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX651.40K ≈ $79.26 |
GBX-971.50K ≈ $-118.20 |
-1.491x | -47.23% |
| 2023-12-31 | GBX1.19 Million ≈ $145.23 |
GBX-1.21 Million ≈ $-147.11 |
-1.013x | -155.38% |
| 2022-12-31 | GBX2.09 Million ≈ $254.07 |
GBX-828.26K ≈ $-100.78 |
-0.397x | +52.34% |
| 2021-12-31 | GBX2.13 Million ≈ $259.12 |
GBX-1.77 Million ≈ $-215.63 |
-0.832x | -120.69% |
| 2020-12-31 | GBX3.66 Million ≈ $444.99 |
GBX-1.38 Million ≈ $-167.79 |
-0.377x | +53.81% |
| 2019-12-31 | GBX987.34K ≈ $120.13 |
GBX-806.00K ≈ $-98.07 |
-0.816x | +46.56% |
| 2018-12-31 | GBX879.94K ≈ $107.06 |
GBX-1.34 Million ≈ $-163.56 |
-1.528x | -105.62% |
| 2017-12-31 | GBX1.28 Million ≈ $155.71 |
GBX-950.80K ≈ $-115.68 |
-0.743x | -105.70% |
| 2016-12-31 | GBX1.04 Million ≈ $126.66 |
GBX-376.00K ≈ $-45.75 |
-0.361x | +73.14% |
| 2015-12-31 | GBX641.00K ≈ $77.99 |
GBX-862.00K ≈ $-104.88 |
-1.345x | -312.13% |
| 2014-12-31 | GBX1.04 Million ≈ $126.78 |
GBX-340.00K ≈ $-41.37 |
-0.326x | -1194.68% |
| 2013-12-31 | GBX3.45 Million ≈ $420.01 |
GBX-87.00K ≈ $-10.59 |
-0.025x | +71.96% |
| 2012-12-31 | GBX3.60 Million ≈ $438.62 |
GBX-324.00K ≈ $-39.42 |
-0.090x | -131.49% |
| 2011-12-31 | GBX3.49 Million ≈ $424.63 |
GBX996.00K ≈ $121.18 |
0.285x | +238.91% |
| 2010-12-31 | GBX2.96 Million ≈ $359.78 |
GBX249.00K ≈ $30.30 |
0.084x | -70.70% |
| 2009-12-31 | GBX2.63 Million ≈ $319.63 |
GBX755.00K ≈ $91.86 |
0.287x | +323.05% |
| 2008-12-31 | GBX1.43 Million ≈ $173.75 |
GBX-184.00K ≈ $-22.39 |
-0.129x | -194.06% |
| 2007-12-31 | GBX1.17 Million ≈ $142.11 |
GBX160.00K ≈ $19.47 |
0.137x | +284.62% |
| 2006-12-31 | GBX903.00K ≈ $109.87 |
GBX-67.00K ≈ $-8.15 |
-0.074x | +74.52% |
| 2005-12-31 | GBX388.00K ≈ $47.21 |
GBX-113.00K ≈ $-13.75 |
-0.291x | -273.91% |
| 2004-12-31 | GBX836.00K ≈ $101.72 |
GBX140.00K ≈ $17.03 |
0.167x | +255.45% |
| 2003-12-31 | GBX-789.00K ≈ $-96.00 |
GBX85.00K ≈ $10.34 |
-0.108x | -113.63% |
| 2002-12-31 | GBX-935.00K ≈ $-113.76 |
GBX-739.00K ≈ $-89.91 |
0.790x | +539.60% |
| 2001-12-31 | GBX-1.17 Million ≈ $-142.11 |
GBX210.00K ≈ $25.55 |
-0.180x | -288.74% |
| 2000-12-31 | GBX-3.99 Million ≈ $-485.35 |
GBX-380.00K ≈ $-46.24 |
0.095x | +76.88% |
| 1999-12-31 | GBX-3.17 Million ≈ $-386.31 |
GBX-171.00K ≈ $-20.81 |
0.054x | -94.55% |
| 1998-12-31 | GBX-2.76 Million ≈ $-335.57 |
GBX-2.72 Million ≈ $-331.43 |
0.988x | +138.27% |
| 1997-12-31 | GBX1.03 Million ≈ $125.32 |
GBX-2.66 Million ≈ $-323.40 |
-2.581x | -1497.58% |
| 1996-12-31 | GBX10.93 Million ≈ $1.33K |
GBX2.02 Million ≈ $245.53 |
0.185x | +1283.15% |
| 1995-12-31 | GBX12.21 Million ≈ $1.49K |
GBX163.00K ≈ $19.83 |
0.013x | -95.81% |
| 1994-12-31 | GBX10.48 Million ≈ $1.27K |
GBX3.34 Million ≈ $405.89 |
0.318x | +748.91% |
| 1993-12-31 | GBX8.26 Million ≈ $1.01K |
GBX310.00K ≈ $37.72 |
0.038x | -90.31% |
| 1992-12-31 | GBX7.03 Million ≈ $855.47 |
GBX2.72 Million ≈ $331.19 |
0.387x | +249.12% |
| 1991-12-31 | GBX9.33 Million ≈ $1.14K |
GBX-2.42 Million ≈ $-294.69 |
-0.260x | -- |
About N4 Pharma PLC
N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequen… Read more